Immune monitoring for precision medicine in allergy and asthma

Boyd, Scott D.; Hoh, Ramona A.; Galli, Stephen J.

doi:10.1016/j.coi.2017.08.007

Cited by 17 publications

(13 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It will also complement currently available tools aimed at developing personalized or precision medicinal approaches for the diagnosis, management, and treatment monitoring of allergic disease. 11 The platform was exploited to identify development of recognition of linear epitopes by IgG, IgG 4 , and IgE in serum/plasma during 3 years of AIT against birch and grass pollen allergy.…”

mentioning

confidence: 99%

Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy

Mikus

Zandian

Sjöberg

et al. 2021

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Background: The interaction of allergens and allergen-specific IgE initiates the allergic cascade after crosslinking of receptors on effector cells. Antibodies of other isotypes may modulate such a reaction. Receptor crosslinking requires binding of antibodies to multiple epitopes on the allergen. Limited information is available on the complexity of the epitope structure of most allergens. Objectives: We sought to allow description of the complexity of IgE, IgG 4 , and IgG epitope recognition at a global, allergomewide level during allergen-specific immunotherapy (AIT). Methods: We generated an allergome-wide microarray comprising 731 allergens in the form of more than 172,000 overlapping 16-mer peptides. Allergen recognition by IgE, IgG 4 , and IgG was examined in serum samples collected from subjects undergoing AIT against pollen allergy. Results: Extensive induction of linear peptide-specific Phl p 1and Bet v 1-specific humoral immunity was demonstrated in subjects undergoing a 3-year-long AIT against grass and birch pollen allergy, respectively. Epitope profiles differed between subjects but were largely established already after 1 year of AIT, suggesting that dominant allergen-specific antibody clones remained as important contributors to humoral immunity following their initial establishment during the early phase of AIT. Complex, subject-specific patterns of allergen isoform and group cross-reactivities in the repertoires were observed, patterns that may indicate different levels of protection against different allergen sources. Conclusions: The study highlights the complexity and subject-specific nature of allergen epitopes recognized following AIT. We envisage that epitope deconvolution will be an important aspect of future efforts to describe and analyze the outcomes of AIT in a personalized manner. (J Allergy Clin Immunol 2020;nnn:nnn-nnn.)

show abstract

mentioning

confidence: 99%

Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy

Mikus

Zandian

Sjöberg

et al. 2021

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…13,112 The "omics" revolution is based on platform technologies in genomics (by far the most robust), metabolomics, proteomics, epigenomics, transcriptomics, lipidomics, and microbiomics to generate vast global datasets, and advanced bioinformatics to interrogate and interpret the datasets using machine learning and artificial intelligence (Figure 4). 113 Such analysis of population-based datasets can reveal novel insights to underpin therapeutic selection from an expanded range of precise biologicals. 114 Examples are emerging from patients with inborn errors of immunity (IEI) in whom the genetically defined defect can be specifically targeted with therapeutics.…”

Section: Precision Medicine and Immune Monitoring Of Allergic Diseasesmentioning

confidence: 99%

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Breiteneder

Diamant

Eiwegger

et al. 2019

Allergy

101

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. AbstractThe specialties of allergy and clinical immunology have entered the era of precision medicine with the stratification of diseases into distinct disease subsets, specific diagnoses, and targeted treatment options, including biologicals and small molecules.This article reviews recent developments in research and patient care and future trends in the discipline. The section on basic mechanisms of allergic diseases summarizes the current status and defines research needs in structural biology, type 2 inflammation, immune tolerance, neuroimmune mechanisms, role of the microbiome and diet, environmental factors, and respiratory viral infections. In the section on diagnostic challenges, clinical trials, precision medicine and immune monitoring Zuzana Diamanthttps://orcid.org/0000-0003-0133-0100Thomas Eiwegger https://orcid.org/0000-0002-2914-7829Wytske J. Fokkens https://orcid.org/0000-0003-4852-229X

show abstract

“…While asthma control has typically been evaluated on the basis of symptoms, lung function and exacerbations, it was noted that measures beyond forced expiratory volume in the first second (FEV1), such as airway inflammatory markers, immune monitoring, clinical and functional assessments, quality of life and the association between sputum cell counts and exacerbations, may provide a more comprehensive evaluation of the response to treatment [54][55][56].…”

Section: Individualisation Of Treatment Response Monitoringmentioning

confidence: 99%

Severe T2-high asthma in the biologics era: European experts' opinion

et al. 2019

View full text Add to dashboard Cite

The European Respiratory Biologics Forum gathered participants from 21 countries in Madrid, Spain, to discuss the management and treatment of severe asthma in the era of biologics. The current insights on the pathophysiology of severe asthma were discussed, as well as the role of respiratory biologics in clinical practice and strategies for eliminating chronic use of oral corticosteroids. The participants also highlighted the key challenges in identifying patients with severe asthma based on phenotypes, biomarkers and treatable traits, and the existing problems in patient referral to specialist care. The monitoring of treatment was debated and the need for a change towards precision medicine and personalised care was emphasised throughout the meeting. This review provides a summary of the discussions and highlights important concerns identified by the participants regarding the current management of severe asthma.

show abstract

Immune monitoring for precision medicine in allergy and asthma

Cited by 17 publications

References 84 publications

Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy

Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Severe T2-high asthma in the biologics era: European experts' opinion

Contact Info

Product

Resources

About